Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease

Código QR

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease

Eman Al Sulais, 1 Turki AlAmeel 2 1Department of Medicine, Royal Commission Hospital, Jubail, Saudi Arabia; 2Department of Medicine, King Fahad Specialist Hospital, Dammam, Saudi ArabiaCorrespondence: Eman Al SulaisDepartment of Medicine, Royal Commission Hospital, P.O. Box 496, Jubail, Qatif 3191...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Al Sulais E, AlAmeel T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	biosimilars inflammatory bowel disease tumor necrosis factor inhibitors Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8b0f7337174e4d028df9e7df5dafc9aa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
por: Rawla P, et al.
Publicado: (2018)

Association of tumor necrosis factor-α and -β gene polymorphisms in inflammatory bowel disease
por: Al-Meghaiseeb ES, et al.
Publicado: (2016)

Biosimilars and the extrapolation of indications for inflammatory conditions
por: Tesser JRP, et al.
Publicado: (2017)

Seminars in inflammatory bowel disease
Publicado: (2001)

A practical guide about biosimilar data for health care providers treating inflammatory diseases
por: Markenson J, et al.
Publicado: (2017)

Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management
por: Igor G. Bakulin, et al.
Publicado: (2021)

Attributes of intestinal microbiota composition and their correlation with clinical primary nonresponse to anti-TNF-α agents in inflammatory bowel disease patients
por: Hanan Alatawi, et al.
Publicado: (2021)

The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment
por: Jin-Woo Kim, et al.
Publicado: (2021)

Factors associated with adherence to treatment in Iranian patients with inflammatory bowel disease
por: Zohre Forouzan, et al.
Publicado: (2021)

The Changing Face of Inflammatory Bowel Disease: Etiology, Physiopathology, Epidemiology
por: Giovanni Clemente Actis
Publicado: (2016)

Biosimilars: presumption of guilt
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2011)

Positioning Aeromonas Infection in Inflammatory Bowel Disease: A Retrospective Analysis
por: Tiago Pereira Guedes, et al.
Publicado: (2021)

From bowel inflammation to the bone and joints: musculoskeletal examination in inflammatory bowel disease (IBD)
por: Samane Tavassoli, et al.
Publicado: (2021)

Fecal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease patients with irritable bowel syndrome-type symptoms
por: Xiufang Cui, et al.
Publicado: (2021)

Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
por: Javier P. Gisbert, et al.
Publicado: (2021)

Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy
por: Dagmar Schierova, et al.
Publicado: (2021)

Psoriasis and inflammatory bowel disease: links and risks
por: Vlachos C, et al.
Publicado: (2016)

Phenotypic profile of peripheral blood lymphocytes in patients with inflammatory bowel diseases
por: M. M. Zafranskaya, et al.
Publicado: (2021)

Intestinal Macrophage Autophagy and its Pharmacological Application in Inflammatory Bowel Disease
por: Yang Zheng, et al.
Publicado: (2021)

Epidemiology of Inflammatory Bowel Diseases (IBD) in Iran: A Review of 740 Patients in Fars Province, Southern Iran
por: Seyed Alireza Taghavi, et al.
Publicado: (2013)

Metabolomics Insights into Inflammatory Bowel Disease: A Comprehensive Review
por: Laila Aldars-García, et al.
Publicado: (2021)

Frequency of Oral Manifestation in Patients with Inflammatory Bowel Disease in Chile
por: Oviedo,C, et al.
Publicado: (2017)

Extracellular vesicles derived from gut microbiota in inflammatory bowel disease and colorectal cancer
por: Giusi Alberti, et al.
Publicado: (2021)

Biosimilars in the management of neutropenia: focus on filgrastim
por: Caselli D, et al.
Publicado: (2016)

Epstein–Barr Virus Prevalence at Diagnosis and Seroconversion during Follow-Up in Pediatric Inflammatory Bowel Disease
por: Jennifer Bachmann, et al.
Publicado: (2021)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald T, et al.
Publicado: (2021)

Editorial: Game Changers in Inflammatory Bowel Diseases
por: Anita Bálint, et al.
Publicado: (2021)

MSC therapy for inflammatory bowel disease
por: Mikhail A. Konoplyannikov, et al.
Publicado: (2021)

Cinacalcet Targets the Neurokinin-1 Receptor and Inhibits PKCδ/ERK/P65 Signaling to Alleviate Dextran Sulfate Sodium-Induced Colitis
por: Yuehong Chen, et al.
Publicado: (2021)

Liver Pathology in Children with Diagnosed Inflammatory Bowel Disease—A Single Center Experience
por: Urszula Daniluk, et al.
Publicado: (2021)

Validation of the Persian Version of Inflammatory Bowel Disease Questionnaire in Patients Who Referred to Clinics and Hospitals of Birjand University of Medical Sciences, Iran
por: Bita Bijari, et al.
Publicado: (2017)

Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved
por: Luis G. Guijarro, et al.
Publicado: (2021)

Roles of Gut Bacteriophages in the Pathogenesis and Treatment of Inflammatory Bowel Disease
por: Lingling Qv, et al.
Publicado: (2021)

Inflammation‐induced left ventricular fibrosis is partially mediated by tumor necrosis factor‐α
por: Ashmeetha Manilall, et al.
Publicado: (2021)

El polimorfismo genético del factor de necrosis tumoral alfa como factor de riesgo en patología
por: Aguillón G,Juan C, et al.
Publicado: (2002)

Epidemiology of Inflammatory Bowel Diseases (IBD) in Iran: A review of 740 patients in Fars province, Southern Iran
por: Murat Kekilli, et al.
Publicado: (2013)

Does Folic Acid Protect Patients with Inflammatory Bowel Disease from Complications?
por: Alicja Ewa Ratajczak, et al.
Publicado: (2021)

Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
por: Sara Salvador-Martín, et al.
Publicado: (2021)

Review of biologics, biosimilars, and intended copies in rheumatology, and current practice in Iraq
por: Al Ani NA, et al.
Publicado: (2018)

Development of Inflammatory Bowel Disease Is Linked to a Longitudinal Restructuring of the Gut Metagenome in Mice
por: Thomas Sharpton, et al.
Publicado: (2017)